115 related articles for article (PubMed ID: 11790638)
1. Brain proton magnetic resonance spectroscopy in Alzheimer disease: changes after treatment with xanomeline.
Frederick Bd; Satlin A; Wald LL; Hennen J; Bodick N; Renshaw PF
Am J Geriatr Psychiatry; 2002; 10(1):81-8. PubMed ID: 11790638
[TBL] [Abstract][Full Text] [Related]
2. Brain proton magnetic resonance spectroscopy (1H-MRS) in Alzheimer's disease: changes after treatment with xanomeline, an M1 selective cholinergic agonist.
Satlin A; Bodick N; Offen WW; Renshaw PF
Am J Psychiatry; 1997 Oct; 154(10):1459-61. PubMed ID: 9326834
[TBL] [Abstract][Full Text] [Related]
3. The selective muscarinic agonist xanomeline improves both the cognitive deficits and behavioral symptoms of Alzheimer disease.
Bodick NC; Offen WW; Shannon HE; Satterwhite J; Lucas R; van Lier R; Paul SM
Alzheimer Dis Assoc Disord; 1997; 11 Suppl 4():S16-22. PubMed ID: 9339268
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of xanomeline in Alzheimer disease: cognitive improvement measured using the Computerized Neuropsychological Test Battery (CNTB).
Veroff AE; Bodick NC; Offen WW; Sramek JJ; Cutler NR
Alzheimer Dis Assoc Disord; 1998 Dec; 12(4):304-12. PubMed ID: 9876958
[TBL] [Abstract][Full Text] [Related]
5. Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease.
Bodick NC; Offen WW; Levey AI; Cutler NR; Gauthier SG; Satlin A; Shannon HE; Tollefson GD; Rasmussen K; Bymaster FP; Hurley DJ; Potter WZ; Paul SM
Arch Neurol; 1997 Apr; 54(4):465-73. PubMed ID: 9109749
[TBL] [Abstract][Full Text] [Related]
6. Effects of central muscarinic-1 receptor stimulation on blood pressure regulation.
Medina A; Bodick N; Goldberger AL; Mac Mahon M; Lipsitz LA
Hypertension; 1997 Mar; 29(3):828-34. PubMed ID: 9052903
[TBL] [Abstract][Full Text] [Related]
7. Xanomeline and the antipsychotic potential of muscarinic receptor subtype selective agonists.
Mirza NR; Peters D; Sparks RG
CNS Drug Rev; 2003; 9(2):159-86. PubMed ID: 12847557
[TBL] [Abstract][Full Text] [Related]
8. The M₁/M₄ preferring agonist xanomeline reverses amphetamine-, MK801- and scopolamine-induced abnormalities of latent inhibition: putative efficacy against positive, negative and cognitive symptoms in schizophrenia.
Barak S; Weiner I
Int J Neuropsychopharmacol; 2011 Oct; 14(9):1233-46. PubMed ID: 21211109
[TBL] [Abstract][Full Text] [Related]
9. Attenuation of neurodegenerative phenotypes in Alzheimer-like presenilin 1/presenilin 2 conditional double knockout mice by EUK1001, a promising derivative of xanomeline.
Wang D; Yang L; Su J; Niu Y; Lei X; Xiong J; Cao X; Hu Y; Mei B; Hu JF
Biochem Biophys Res Commun; 2011 Jul; 410(2):229-34. PubMed ID: 21651893
[TBL] [Abstract][Full Text] [Related]
10. The utility of salivary amylase as an evaluation of M3 muscarinic agonist activity in Alzheimer's disease.
Sramek JJ; Cutler NR; Hurley DJ; Seifert RD
Prog Neuropsychopharmacol Biol Psychiatry; 1995 Jan; 19(1):85-91. PubMed ID: 7535938
[TBL] [Abstract][Full Text] [Related]
11. Axonal injury and membrane alterations in Alzheimer's disease suggested by in vivo proton magnetic resonance spectroscopic imaging.
Meyerhoff DJ; MacKay S; Constans JM; Norman D; Van Dyke C; Fein G; Weiner MW
Ann Neurol; 1994 Jul; 36(1):40-7. PubMed ID: 8024260
[TBL] [Abstract][Full Text] [Related]
12. Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia.
Shekhar A; Potter WZ; Lightfoot J; Lienemann J; Dubé S; Mallinckrodt C; Bymaster FP; McKinzie DL; Felder CC
Am J Psychiatry; 2008 Aug; 165(8):1033-9. PubMed ID: 18593778
[TBL] [Abstract][Full Text] [Related]
13. Xanomeline suppresses excessive pro-inflammatory cytokine responses through neural signal-mediated pathways and improves survival in lethal inflammation.
Rosas-Ballina M; Valdés-Ferrer SI; Dancho ME; Ochani M; Katz D; Cheng KF; Olofsson PS; Chavan SS; Al-Abed Y; Tracey KJ; Pavlov VA
Brain Behav Immun; 2015 Feb; 44():19-27. PubMed ID: 25063706
[TBL] [Abstract][Full Text] [Related]
14. Conversion from mild cognitive impairment to probable Alzheimer's disease predicted by brain magnetic resonance spectroscopy.
Modrego PJ; Fayed N; Pina MA
Am J Psychiatry; 2005 Apr; 162(4):667-75. PubMed ID: 15800137
[TBL] [Abstract][Full Text] [Related]
15. M1 agonists for the treatment of Alzheimer's disease. Novel properties and clinical update.
Fisher A; Heldman E; Gurwitz D; Haring R; Karton Y; Meshulam H; Pittel Z; Marciano D; Brandeis R; Sadot E; Barg Y; Pinkas-Kramarski R; Vogel Z; Ginzburg I; Treves TA; Verchovsky R; Klimowsky S; Korczyn AD
Ann N Y Acad Sci; 1996 Jan; 777():189-96. PubMed ID: 8624083
[TBL] [Abstract][Full Text] [Related]
16. In vivo proton magnetic resonance spectroscopy of the temporal lobe in Alzheimer's disease.
Frederick BD; Lyoo IK; Satlin A; Ahn KH; Kim MJ; Yurgelun-Todd DA; Cohen BM; Renshaw PF
Prog Neuropsychopharmacol Biol Psychiatry; 2004 Dec; 28(8):1313-22. PubMed ID: 15588758
[TBL] [Abstract][Full Text] [Related]
17. Conversion to dementia in mild cognitive impairment is associated with decline of N-actylaspartate and creatine as revealed by magnetic resonance spectroscopy.
Pilatus U; Lais C; Rochmont Adu M; Kratzsch T; Frölich L; Maurer K; Zanella FE; Lanfermann H; Pantel J
Psychiatry Res; 2009 Jul; 173(1):1-7. PubMed ID: 19427767
[TBL] [Abstract][Full Text] [Related]
18. The muscarinic M1/M4 receptor agonist xanomeline exhibits antipsychotic-like activity in Cebus apella monkeys.
Andersen MB; Fink-Jensen A; Peacock L; Gerlach J; Bymaster F; Lundbaek JA; Werge T
Neuropsychopharmacology; 2003 Jun; 28(6):1168-75. PubMed ID: 12700711
[TBL] [Abstract][Full Text] [Related]
19. Lu 25-109, a muscarinic agonist, fails to improve cognition in Alzheimer's disease. Lu25-109 Study Group.
Thal LJ; Forrest M; Loft H; Mengel H
Neurology; 2000 Jan; 54(2):421-6. PubMed ID: 10668706
[TBL] [Abstract][Full Text] [Related]
20. Correlation of findings in advanced MR techniques with global severity scales in patients with some grade of cognitive impairment.
Fayed N; Dávila J; Oliveros A; Medrano J; Castillo J
Neurol Res; 2010 Mar; 32(2):157-65. PubMed ID: 20158954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
